Drugs / ELUVIXTAMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04478695 | Sep → Oct 2020 | acute myeloid leukemia | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT02520427 | Aug 2015 → Jan 2022 | acute myeloid leukemia, myelodysplastic syndrome | Amgen | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-12-04 | Amgen | Results Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018 amgen.com ↗
Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE ® ) immunotherapies AMG 420 and AMG 330. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-12-04 | Amgen | Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018 amgen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELUVIXTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594521 ↗ |
| Known as | AMG 330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02520427 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594521 ↗ |
| Route | Intravenous | “continuous IV infusion” NCT02520427 ↗ |